I. Transaction Core Details (As of April 20, 2026) Latest Update: Definitive agreement officially announced (total deal value up to $7 billion, including upfront cash plus R&D milestone payments). Structure: Cash upfront combined with milestone payments, consistent with Lilly’s long-standing M&A strategy to mitigate early-stage development risks. Expected Close: Scheduled for the second half of 2026, subject to standard regulatory approvals. II. Strategic Impact Analysis 1. Business: Filling the Oncology Pipeline, Reducing Concentration Risk Core Asset: Kelonia’s proprietary in vivo CAR-T platform (iGPS) — an engineered lentiviral particle system that modifies T-cells directly in the body, eliminating the need for apheresis, ex vivo manufacturing or lymphodepletion, thus streamlini